Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 3, 2007, Pages

  Micek, Scott T ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTOBIPROLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; ORITAVANCIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CONSTIPATION; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; HYPOTENSION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SLEEP DISORDER; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VOMITING;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34548472399     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519471     Document Type: Review

References (45)

1. Albanèse J, Léone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44:1356-8.
2. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-9.
3. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-6.
4. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42(Suppl 1):S40-50.
5. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006; 57:506-10.
6. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
7. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
8. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
9. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
10. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005; 26:442-8.
11. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56:923-9.
12. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565-73.
13. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-53.
14. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732-8.
15. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006; 367:731-9.
16. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202-11.
17. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578-83.
18. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61:525-51.
19. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180-7.
20. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28:345-51.
21. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66-72.
22. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155-63.
23. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113-6.
24. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006; 26:1099-110.
25. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658-66.
26. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
27. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
28. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
29. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
30. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-15.
31. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-80.
32. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-7.
33. Basilea Pharmaceutica. Basilea reports excellent pivotal data for ceftobipriole, a novel anti-MRSA broad-spectrum investigational antibiotic, at ICAAC. Available at: http://www.basilea.com/template_loader.php?tplpage_id= 34&mode=details&id=73Accessed. Accessed 2 February 2007.
34. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 2006; 26:908-18.
35. Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 2006; 4:743-9.
36. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 Study. Antimicrob Agents Chemother 2006; 50:862-7.
37. Theravance. Theravance announces positive results in phase 3 telavancin complicated skin and skin structure infection program. Available at: http://ir.theravance.com/ReleaseDetail.cfm?ReleaseID=208110. Accessed 2 February 2007.
38. Ward KE, Mersfelder TL, LaPlante KL. Oritavancin - an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006; 15:417-29.
39. Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:994-1000.
40. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect 2006; 12(Suppl 2):17-22.
41. Page MG. Anti-MRSA β-lactams in development. Curr Opin Pharmacol 2006; 6:480-5.
42. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-9.
43. Cerexa. Ceftaroline acetate. Available at: http://www.cerexa.com/ products.html. Accessed 2 February 2007.
44. Arpida. Intravenous iclaprim. Available at: http://www.arpida.ch/index. php?MenuID=13&UserID=1&ContentID=65. Accessed 2 February 2007.
45. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27: 227-49.